While PIK3CA mutations are currently targetable in breast cancer, there are no anti-PIK3CA targeted therapies that are FDA approved for NSCLC.35 This finding also suggests a potential rationale for in vitro and clinical investigations into whether PIK3CA mutations hinder NSCLC to metastasize to the brain. This evidence concerns the gene PIK3CA and breast carcinoma.